The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors

Clinical Cancer Research

Volumn 12, Issue 5, 2006, Pages 1470-1478

  Di Modugno, Francesca ^a   Mottolese, Marcella ^a   Di Benedetto, Anna ^a   Conidi, Andrea ^a   Novelli, Flavia ^a   Perracchio, Letizia ^a   Venturo, Irene ^a   Botti, Claudio ^a   Jager, Elke ^c   Santoni, Angela ^b   Natali, Pier Giorgio ^a   Nisticò, Paola ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c KRANKENHAUS NORDWEST   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSKELETON PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MONOCLONAL ANTIBODY; NEU DIFFERENTIATION FACTOR; PROGESTERONE RECEPTOR; PROTEIN HMENA; REGULATOR PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BENIGN TUMOR; BREAST CARCINOGENESIS; BREAST TUMOR; CANCER CELL CULTURE; CANCER RISK; CELL STRAIN MCF 7; CONTROLLED STUDY; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BREAST; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CARCINOMA, PAPILLARY; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; COHORT STUDIES; CYTOSKELETAL PROTEINS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASMS, DUCTAL, LOBULAR, AND MEDULLARY; NEUREGULIN-1; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 33645048173     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2027     Document Type: Article

References (23)

1. Dunn GP, Bruce AT, Sheehan KC, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol 2005;6:722-9.
2. + T-cell immune response. Int J Cancer 2004;109:909-18.
3. Bear JE, Svitkina TM, Krause M, et al. Antagonism between Ena/VASP proteins and actin filament capping regulates fibroblast motility. Cell 2002;109:509-21.
4. Barzik M, Kotova TI, Higgs HN, et al. Ena/VASP proteins enhance actin polymerization in the presence of barbed end capping proteins. J Biol Chem 2005;280:28653-62.
5. Krause M, Dent EW, Bear JE, Loureiro JJ, Gertler FB. Ena/VASP proteins: regulators of the actin cytoskeleton and cell migration. Annu Rev Cell Dev Biol 2003;19:541-64.
6. Vasioukhin V, Bauer C, Yin M, Fuchs E. Directed actin polymerization is the driving force for epithelial cell-cell adhesion. Cell 2000;100:209-19.
7. Wulfkuhle JD, Sgroi DC, Krutzsch H, et al. Proteomics of human breast ductal carcinoma in situ. Cancer Res 2002;62:6740-9.
8. Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004;117:927-39.
9. Wang W, Goswami S, Lapidus K, et al. Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors. Cancer Res 2004;64:8585-94.
10. Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med 2005;353:229-37.
11. Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003;95:142-53.
12. Fitzgibbons PL, Henson DE, Hutter RV. Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement. Cancer Committee of the College of the American Pathologists. Arch Pathol Lab Med 1998;124:966-78.
13. Tavassoli FA, Devilee P. Tumors of the breast. In: Tavassoli FA, Devilee P. Pathology and genetics. Tumours of the breast and female genital organs. Chapter 1. Lyon (France): IARC Press: 2003. p. 9-112.
14. Digiesi G, Giacomini P, Fraioli R, et al. Production and characterization of murine mAbs to the extracellular domain of human neu oncogene product GP185HER-2. Hybridoma 1992;11:519-27
15. Rao JY, Li N. Microfilament actin remodeling as a potential target for cancer drug development. Curr Cancer Drug Targets 2004;4:345-54.
16. Lu QY, Jin YS, Pantuck A, et al. Green tea extract modulates actin remodeling via Rho activity in an in vitro multistep carcinogenic model. Clin Cancer Res 2005;11:1675-83.
17. Bast RC, Jr., Ravdin P, Hayes DF, et al. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-78.
18. Ellsworth DL, Ellsworth RE, Liebman MN, Hooke JA, Shriver CD. Genomic instability in histological normal breast tissues: implications for carcinogenesis. Lancet Oncol 2004;5:753-8.
19. Auerbuch V, Loureiro JJ, Gertler FB, Theriot JA, Portnoy DA. Ena/VASP proteins contribute to Listeria monocytogenes pathogenesis by controlling temporal and spatial persistence of bacterial actin based motility Mol Microbiol 2003;49:1361-75.
20. Menzies AS, Aszodi A, Williams SE, et al. Mena and vasodilator-stimulated phosphoprotein are required for multiple actin-dependent processes that shape the vertebrate nervous system. J Neurosci 2004;24:8029-38.
21. Astolfi A, Landuzzi L, Nicoletti G, et al. Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. Am J Pathol 2005;166:1205-16.
22. Stove C, Bracke M. Roles for neuregulins in human cancer. Clin Exp Metastasis 2004;21:665-84.
23. Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J, Kumar R. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J Biol Chem 1998;273:28238-46.